Egetis Therapeutics AB (publ) (EGTX.ST)
SEK 3.38
(-3.43%)
SEK 3.38
(-3.43%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 760.2 Million SEK | 35.48% |
| 2022 | 561.1 Million SEK | -1.43% |
| 2021 | 569.26 Million SEK | -36.32% |
| 2020 | 893.96 Million SEK | 231.01% |
| 2019 | 270.07 Million SEK | 11.58% |
| 2018 | 242.03 Million SEK | -23.25% |
| 2017 | 315.36 Million SEK | -20.45% |
| 2016 | 396.43 Million SEK | 657.12% |
| 2015 | 52.36 Million SEK | -49.39% |
| 2014 | 103.46 Million SEK | 102.83% |
| 2013 | 51.01 Million SEK | -15.62% |
| 2012 | 60.45 Million SEK | -33.87% |
| 2011 | 91.42 Million SEK | 976.56% |
| 2010 | 8.49 Million SEK | 43.58% |
| 2009 | 5.91 Million SEK | 10.12% |
| 2008 | 5.37 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 700 Million SEK | -7.92% |
| 2024 Q2 | 646.6 Million SEK | -7.63% |
| 2023 Q1 | 676.1 Million SEK | 20.5% |
| 2023 Q3 | 534.1 Million SEK | -12.27% |
| 2023 Q2 | 608.8 Million SEK | -9.95% |
| 2023 Q4 | 760.2 Million SEK | 42.33% |
| 2023 FY | 760.2 Million SEK | 35.48% |
| 2022 Q3 | 617.6 Million SEK | -6.58% |
| 2022 FY | 561.1 Million SEK | -1.43% |
| 2022 Q4 | 561.1 Million SEK | -9.15% |
| 2022 Q1 | 534.82 Million SEK | -6.05% |
| 2022 Q2 | 661.11 Million SEK | 23.61% |
| 2021 Q1 | 850.75 Million SEK | -4.83% |
| 2021 Q3 | 777.37 Million SEK | -6.51% |
| 2021 FY | 569.26 Million SEK | -36.32% |
| 2021 Q4 | 569.26 Million SEK | -26.77% |
| 2021 Q2 | 831.51 Million SEK | -2.26% |
| 2020 FY | 893.96 Million SEK | 231.01% |
| 2020 Q3 | 164 Million SEK | -15.12% |
| 2020 Q4 | 893.96 Million SEK | 445.1% |
| 2020 Q2 | 193.2 Million SEK | -17.47% |
| 2020 Q1 | 234.1 Million SEK | -13.32% |
| 2019 Q1 | 266.05 Million SEK | 9.92% |
| 2019 FY | 270.07 Million SEK | 11.58% |
| 2019 Q4 | 270.07 Million SEK | -7.28% |
| 2019 Q3 | 291.27 Million SEK | -10.2% |
| 2019 Q2 | 324.37 Million SEK | 21.92% |
| 2018 Q4 | 242.03 Million SEK | -4.8% |
| 2018 FY | 242.03 Million SEK | -23.25% |
| 2018 Q3 | 254.24 Million SEK | -9.56% |
| 2018 Q2 | 281.12 Million SEK | -6.31% |
| 2018 Q1 | 300.04 Million SEK | -4.86% |
| 2017 Q1 | 386.61 Million SEK | -2.48% |
| 2017 Q4 | 315.36 Million SEK | -11.72% |
| 2017 Q3 | 357.23 Million SEK | -2.93% |
| 2017 FY | 315.36 Million SEK | -20.45% |
| 2017 Q2 | 368 Million SEK | -4.81% |
| 2016 Q2 | 41.22 Million SEK | -7.71% |
| 2016 Q3 | 26.04 Million SEK | -36.83% |
| 2016 Q4 | 396.43 Million SEK | 1422.41% |
| 2016 FY | 396.43 Million SEK | 657.12% |
| 2016 Q1 | 44.66 Million SEK | -14.69% |
| 2015 Q1 | 88.45 Million SEK | -14.51% |
| 2015 Q4 | 52.36 Million SEK | -16.25% |
| 2015 FY | 52.36 Million SEK | -49.39% |
| 2015 Q2 | 73.88 Million SEK | -16.46% |
| 2015 Q3 | 62.52 Million SEK | -15.38% |
| 2014 Q3 | 44.22 Million SEK | -13.36% |
| 2014 Q1 | 42.61 Million SEK | -16.47% |
| 2014 FY | 103.46 Million SEK | 102.83% |
| 2014 Q4 | 103.46 Million SEK | 133.94% |
| 2014 Q2 | 51.05 Million SEK | 19.81% |
| 2013 Q3 | 56.92 Million SEK | -7.17% |
| 2013 Q4 | 51.01 Million SEK | -10.39% |
| 2013 Q2 | 61.32 Million SEK | 21.57% |
| 2013 Q1 | 50.44 Million SEK | -16.56% |
| 2013 FY | 51.01 Million SEK | -15.62% |
| 2012 Q2 | 71.63 Million SEK | -13.03% |
| 2012 Q3 | 67.5 Million SEK | -5.76% |
| 2012 Q1 | 82.35 Million SEK | -9.92% |
| 2012 Q4 | 60.45 Million SEK | -10.44% |
| 2012 FY | 60.45 Million SEK | -33.87% |
| 2011 Q2 | 118.24 Million SEK | 879.45% |
| 2011 FY | 91.42 Million SEK | 976.56% |
| 2011 Q4 | 91.42 Million SEK | -20.52% |
| 2011 Q3 | 115.02 Million SEK | -2.72% |
| 2011 Q1 | 12.07 Million SEK | 42.16% |
| 2010 Q4 | 8.49 Million SEK | 0.0% |
| 2010 FY | 8.49 Million SEK | 43.58% |
| 2009 FY | 5.91 Million SEK | 10.12% |
| 2008 FY | 5.37 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Asarina Pharma AB (publ) | 6.07 Million SEK | -12409.462% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | -53.19% |
| NextCell Pharma AB | 81.28 Million SEK | -835.193% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -2419.468% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | -16.326% |
| AcouSort AB (publ) | 34.51 Million SEK | -2102.648% |
| OncoZenge AB (publ) | 20.34 Million SEK | -3637.463% |
| Xintela AB (publ) | 18.39 Million SEK | -4032.645% |
| Ziccum AB (publ) | 14.97 Million SEK | -4977.478% |
| Active Biotech AB (publ) | 44 Million SEK | -1627.727% |
| Alzinova AB (publ) | 123.18 Million SEK | -517.101% |
| Amniotics AB (publ) | 26.08 Million SEK | -2814.207% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -541.79% |
| BioArctic AB (publ) | 1.18 Billion SEK | 35.906% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 60.001% |
| Camurus AB (publ) | 1.9 Billion SEK | 60.153% |
| Cantargia AB (publ) | 223.71 Million SEK | -239.812% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -5012.65% |
| CombiGene AB (publ) | 120.61 Million SEK | -530.286% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -250.261% |
| Genovis AB (publ.) | 288.85 Million SEK | -163.175% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -791.971% |
| Mendus AB (publ) | 755.95 Million SEK | -0.562% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -440.694% |
| Kancera AB (publ) | 65.64 Million SEK | -1058.082% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 39.59% |
| LIDDS AB (publ) | 17.65 Million SEK | -4205.862% |
| Lipum AB (publ) | 12.11 Million SEK | -6177.457% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -2162.365% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -172.722% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -3693.224% |
| Saniona AB (publ) | 64.14 Million SEK | -1085.164% |
| Simris Alg AB (publ) | 174.55 Million SEK | -335.515% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 0.662% |
| Intervacc AB (publ) | 259.61 Million SEK | -192.823% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -1118.718% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -1711.769% |
| Corline Biomedical AB | 100.1 Million SEK | -659.403% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -329.198% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -1123.13% |
| Aptahem AB (publ) | 63.02 Million SEK | -1106.189% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | -116.375% |
| Fluicell AB (publ) | 9.34 Million SEK | -8039.186% |
| Biovica International AB (publ) | 131.4 Million SEK | -478.504% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -1334.746% |
| Abliva AB (publ) | 87.49 Million SEK | -768.81% |
| 2cureX AB (publ) | 16.62 Million SEK | -4472.632% |
| I-Tech AB | 152.44 Million SEK | -398.678% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 25.327% |
| Cyxone AB (publ) | 43.65 Million SEK | -1641.381% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -866.045% |
| Biosergen AB | 7.2 Million SEK | -10456.867% |
| Nanologica AB (publ) | 77.42 Million SEK | -881.803% |
| SynAct Pharma AB | 228.01 Million SEK | -233.393% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -2740.489% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 45.707% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -3402.762% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -218.905% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -8891.13% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -773.071% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -2566.62% |